Temozolomide-Derived AIC Is Incorporated into Purine Synthesis in Glioblastoma

Area of Science:

• Oncology
• Biochemistry
• Molecular Biology

Background:

• Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis.
• Temozolomide (TMZ) is a standard chemotherapy, but its efficacy is limited.
• TMZ's mechanism involves DNA alkylation, ATP/NAD+ depletion, and AIC byproduct release.

Purpose of the Study:

• To investigate if the TMZ byproduct 4-amino-5-imidazole carboxamide (AIC) can be incorporated into cellular purines.
• To determine if AIC contributes to purine synthesis pathways in glioblastoma.
• To assess the potential for AIC to antagonize TMZ's anticancer effects.

Main Methods:

• Utilized isotope-labeled TMZ and mass spectrometry to trace AIC metabolism.
• Analyzed AIC incorporation into AMP and NAD+ in glioblastoma cell lines.
• Examined transcriptomic data from TCGA and GTEx databases for purine synthesis pathway activity.

Main Results:

• Demonstrated that AIC derived from TMZ is incorporated into AMP and NAD+ in glioblastoma cells.
• Confirmed AIC's entry into the de novo purine synthesis pathway.
• Found that de novo purine synthesis is upregulated in GBM compared to normal brain tissue.

Conclusions:

• The drug metabolite AIC from TMZ can be incorporated into cellular purines via the de novo synthesis pathway.
• Upregulated de novo purine synthesis in GBM may provide a salvage pathway for AIC, potentially reducing TMZ efficacy.
• These findings highlight a novel mechanism of drug resistance and suggest therapeutic strategies targeting purine metabolism in GBM.